Current Position and Future Perspectives of Melatonin and Its Supplements in Pulmonary Hypertension
Mustafa Yıldız
, Sahra Asena Balcıoğlu
Department of Cardiology, İstanbul University-Cerrahpaşa, Institute of Cardiology, İstanbul, Türkiye
Keywords: Inflammation; melatonin; pulmonary hypertension; supplement.
Abstract
Melatonin, which is secreted principally by the pineal gland at night, affects several cardiovascular conditions including arterial hemodynamics, right ventricle functions, and pulmonary artery functions. Pulmonary hypertension is a hemodynamic and pathophysiological condition defined as an increase of average pulmonary artery pressure exceeding 20 mmHg at rest. In the light of the literature data, as discussed in this study, melatonin and its supplements may play a role in the pathogenesis and treatment of pulmonary hypertension.
Cite This Article: Yıldız M, Balcıoğlu SA. Current Position and Future Perspectives of Melatonin and Its Supplements in Pulmonary Hypertension. Koşuyolu Heart J 2024;27(1):37–39.
Externally peer-reviewed.
Concept – M.Y., S.A.B.; Design – M.Y., S.A.B.; Supervision – M.Y., S.A.B.; Literature search – M.Y., S.A.B.; Writing – M.Y., S.A.B.; Critical review – M.Y., S.A.B.
All authors declared no conflict of interest.
Not declared.
The authors declared that this study received no financial support.